May 20, 2020

GM proposes $2.8bn 10-year investment in South Korea as crisis talks with government continue

South Korea
General Motors
GM Korea
Gunsang
2 min
GM proposes $2.8bn 10-year investment in South Korea as crisis talks with government continue

Further to government talks and a proposed debt-to-equity swap yesterday, General Motors has proposed an investment of $2.8bn in its loss making South Korean business, GM South Korea.

The total value is to be invested over 10 years. GM has asked the South Korean government to contribute toward this.

This follows the announcement that one facility will be shut down and the rest in the country remain in jeopardy.

GM has requested that South Korea invest up to $476mn through the Korean Development Bank, which owns 17% of GM South Korea.

See also:

GM’s proposed $2.2bn debt to equity swap to save Korea business

ASEAN Business and Investment Summit

Singapore to limit number of cars on the roads in 2018

The previous $2.2bn debt-for-equity swap which is being used to gain financial support and tax benefits from Seoul is still proposed alongside this investment.

South Korea’s trade minister, Paik Un-gyu, told parliament that GM has been asked to be more transparent about its finances and operations in the country if Korea can be expected to invest in the business. He also stated that a long-term commitment to the country will have to be made prior to any investment.

GM South Korea currently employs 16,000 workers of which 14,000 are members of the GM Korea Union, which has promised to strike if the company decides to leave the country. The Union is putting increasing pressure on GM to come up with a plan as jobs are on the line.

Previously, South Korea was an export hub for GM and produced up to a fifth of its global output.

The closure of the Gunsan plant is part of a series of steps to make the company more profitable. GM has also pulled out entirely from other markets.

Between 2014 and 2016 according to CNBC, GM Korea reported net losses of $1.9trn.

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article